- Home
- COCH vs ITRM Comparison
COCH vs ITRM Comparison
Compare COCH & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | COCH | ITRM |
|---|---|---|
| Founded | 1995 | 2015 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.4M | 24.3M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | COCH | ITRM |
|---|---|---|
| Price | $0.81 | $0.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $9.50 | $9.00 |
| AVG Volume (30 Days) | 448.5K | ★ 1.2M |
| Earning Date | 11-10-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $208,000.00 | ★ $390,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $29.53 | $325.95 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.64 | $0.36 |
| 52 Week High | $2.25 | $2.18 |
Technical Indicators
Market Signals| Indicator | COCH | ITRM |
|---|---|---|
| Relative Strength Index (RSI) | 50.34 | 43.07 |
| Support Level | $0.80 | $0.44 |
| Resistance Level | $0.86 | $0.48 |
| Average True Range (ATR) | 0.05 | 0.04 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 59.29 | 37.40 |
Price Performance
Historical ComparisonAbout COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life. The Company has one reportable segment: hearing. The hearing segment derives revenue from the sale of the Esteem FI-AMEI implants and replacement components to Esteem FI-AMEI implants.
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.